J. Anderson

发表

The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO study

J. Rosenstock, G. Umpierrez, T. Blevins, 2011, Diabetes, obesity & metabolism.

Graphical human insulin time-activity profiles using standardized definitions.

J H Anderson, J. Anderson, J. Woodworth, 2001, Diabetes technology & therapeutics.

Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure.

L. Vignati, M. Trautmann, J. Anderson, 1999, Clinical therapeutics.

Impact of insulin lispro on HbA1c values in insulin pump users

H. Chase, S. Garg, J. Anderson, 2000, Diabetes, obesity & metabolism.

Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.

M. Trautmann, J. Anderson, P. Roach, 1999, Clinical therapeutics.

Effect of dietary composition on insulin receptors in normal subjects.

W. Blackard, J. Anderson, J. P. Wigand, 1979, The American journal of clinical nutrition.

Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

P. Iversen, L. Vignati, J. Anderson, 1997, Clinical therapeutics.

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

L. Vignati, R. DiMarchi, V. Koivisto, 1997, Archives of internal medicine.

Immunologic Effects of Insulin Lispro [Lys (B28), Pro (B29) Human Insulin] in IDDM and NIDDM Patients Previously Treated With Insulin

N. Fineberg, J. Anderson, M. Birkett, 1996, Diabetes.

Mixing insulins in 1990.

J. Anderson, R. Campbell, 1990, The Diabetes educator.

Diabetes and hypoglycemia due to insulin antibodies.

W. Blackard, J. Anderson, J. Goldman, 1978, The American journal of medicine.

Pre‐meal Insulin Analogue Insulin Lispro vs Humulin® R Insulin Treatment in Young Subjects with Type 1 Diabetes

H. Chase, S. Garg, L. Vignati, 1996, Diabetic medicine : a journal of the British Diabetic Association.

Presence of Insulin Autoantibodies as Regular Feature of Nondiabetic Repertoire of Immunity

N. Fineberg, J. Anderson, S. Fineberg, 1991, Diabetes.

Effects of a short-acting insulin analog (Insulin Lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus.

A. de Leiva, A. Caixàs, J. Ordóñez‐Llanos, 1998, Metabolism: clinical and experimental.

Long‐term efficacy of Humalogã in subjects with Type 1 diabetes mellitus

H. Chase, J. Anderson, JamesH. Anderson, 1999, Diabetic medicine : a journal of the British Diabetic Association.

Anti-insulin receptor antibodies and diabetes.

W. Blackard, J. Anderson, F. Mullinax, 1977, Annals of internal medicine.

Hyperresponsiveness to tolbutamide of dogs pretreated with diazoxide.

W. Blackard, J. Anderson, G. Byrd, 1971, Metabolism: Clinical and Experimental.

Mixing Insulin Lispro and Ultralente Insulin

J. Clore, J. Anderson, E. Bastyr, 1997, Diabetes Care.

Hyperinsulinism in endotoxin shock dogs.

J. Spitzer, W. Blackard, J. Anderson, 1976, Metabolism: clinical and experimental.

Effect of lithium on pancreatic islet insulin release.

W. Blackard, J. Anderson, J. Anderson, 1978, Endocrinology.

Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD‐5)

J. Chien, M. Heathman, S. Berry, 2014, Diabetes, obesity & metabolism.

The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes.

H. Chase, S. Garg, J. Anderson, 2001, Diabetes care.